BI-907828,Doxorubicin
Boehringer Ingelheim,Teva Pharmaceuticals,sopherion
['impact,(-impacte),(-impacti),(-impactf)', 'boehringer']
#hcp: transforming cancer care requires a diversity of minds and together, we can make a bigger impact. at #esmo22, researcher is presenting phase 1 data from our mdm2-p53 antagonist, which led to the initiation of our ongoing brightline-1 trial in ddlps
Let’s connect for better health.